AN OPEN-LABEL EXTENSION STUDY OF OLEZARSEN (ISIS 678354) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG)

Registry ID

ISIS 678354-CS15

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

IONIS PHARMACEUTICALS INC

Start date

2025-05-12

Last update

2023-02-07

Conditions

• HYPERTRIGLYCERIDEMIA

Related clinical trials

• A PHASE 2, OPEN-LABEL TRIAL EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF ION775 IN ADULTS WITH HYPERTRIGLYCERIDEMIA
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SOLARIS-1)
• A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)
• DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2 STUDY OF ISIS 678354 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)

View on source registry